Percutaneous left atrial appendage occlusion with a Watchman device following recurrent stroke on warfarin and rivaroxaban in patient with paroxysmal atrial fibrillation.
The optimal management of recurrent cardioembolic stroke in a patient on oral anticoagulation is controversial. Therapeutic strategies for secondary stroke prevention in such circumstances may include the intensification of oral anticoagulation, the addition of antiplatelet therapy to warfarin, or the use of a non-vitamin K antagonist instead of warfarin. However, there is no evidence to support these interventions, and indeed these strategies are not endorsed by the 2011 Guidelines on the Secondary Prevention of Stroke issued by the American Heart Association/American Stroke Association. Percutaneous occlusion of the left atrial appendage (LAA) has recently emerged as an acceptable non-pharmacological strategy to reduce the risk of cardioembolism in patients who cannot tolerate oral anticoagulation, but there is little evidence to support its use in the context of recurrent stroke despite oral anticoagulation. We present the case of a 66 year-old male with paroxysmal atrial fibrillation who experienced recurrent stroke despite treatment with warfarin initially, and rivaroxaban subsequently. After excluding non-cardioembolic causes of recurrent stroke, we proceeded with percutaneous occlusion of the LAA with a Watchman device. Nine months post-procedure he has not experienced recurrence of neurological symptoms. Our case provides anectodal evidence that catheter-based LAA occlusion can be beneficial in secondary stroke prevention where oral anticoagulation has been problematic.
Department of Cardiology, St Vincent's Hospital, 390 Victoria Street, Darlinghurst, Sydney NSW 2010, Australia.
Roberto
R
Spina
Department of Cardiology, St Vincent's Hospital, 390 Victoria Street, Darlinghurst, Sydney NSW 2010, Australia; University of New South Wales, High Street, Kensington, Sydney NSW 2052, Australia.
Rajesh
R
Subbiah
Department of Neurology, St Vincent's Hospital, 390 Victoria Street, Darlinghurst, Sydney NSW 2010, Australia; University of New South Wales, High Street, Kensington, Sydney NSW 2052, Australia.
Romesh
R
Markus
Department of Cardiology, St Vincent's Hospital, 390 Victoria Street, Darlinghurst, Sydney NSW 2010, Australia. Electronic address: gunalingam@bigpond.com.au.
Brendan
B
Gunalingam
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000601:surgery*; D006328:Cardiac Catheterization / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009025:Morpholines / Q000008:administration & dosage*; D000069552:Rivaroxaban; D020521:Stroke / Q000188:drug therapy / Q000209:etiology; D013876:Thiophenes / Q000008:administration & dosage*; D014859:Warfarin / Q000008:administration & dosage*
D000925:Anticoagulants; D009025:Morpholines; D013876:Thiophenes; D014859:Warfarin; D000069552:Rivaroxaban
Left atrial appendage occlusion; Rivaroxaban; Secondary stroke prevention; Stroke prevention in atrial fibrillation; Watchman device